STL Index for: Ingenol Mebutate

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses

A topical formulation combining 0.5% 5-fluorouracil with 10% salicylic acid (5-FU-SA) was introduced in Europe under the trade name Actikerall™ for the treatment of AKs. Now commercially available in Canada, 5-FU-SA represents a patient applied therapeutic option. Clinical trial data is considered.

An Update on the Clinical Management of Cutaneous Molluscum Contagiosum

Molluscum contagiosum is a poxvirus infection of the skin that is commonly observed in children. This articles discusses the molluscum contagiosum virus (MCV), its pathogenesis, mechanism, and treatment modalities.

Actinic Keratosis: A Practical Overview

Actinic keratosis (AK) is a prevalent skin condition that warrants 5.2 million office visits in the US each year. Various treatments for AK, both local and field therapy, and their appropriate use are discussed in this article.

Update on Drugs and Drug News: March-April 2013

Update on Ingenol mebutate gel (0.015%, 0.05%) Picato™, Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), and Hydrogel for skin and wound care (Vashe® Skin and Wound Hydrogel)

Update on Drugs and Drug News: March 2012

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

Ingenol Mebutate: An Introduction

The incidence of nonmelanoma skin cancer continues to increase. This article discusses ingenol mebutate, its history, mechanism of action, and recent trial evidence for this emerging therapy are discussed.

POPULAR